KYNB — Kyntra Bio, Inc.

FibroGen Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $1.1 million for Q3 2025, up from $0.1 million in Q3 2024.
• Operating Costs: $6.5 million, a significant decrease from $47.8 million year-over-year.
• R&D Expenses: $1.2 million, down from $20 million in Q3 2024.
• SG&A Expenses: $5.3 million, reduced from $9.4 million in Q3 2024.
• Net Loss: $13.1 million or $3.25 per share, improved from a net loss of $48.3 million or $12.01 per share in Q3 2024.
• Cash Position: $121.1 million as of September 30, 2025, with a cash runway extended into 2028 following the completion of the FibroGen China sale.

2. Strategic Updates and Business Highlights

• Sale of FibroGen China: Completed for approximately $220 million, providing access to cash and paying off a senior secured term loan, enhancing financial stability.
• FG-3246 Development: Progressing with ongoing Phase II trials for FG-3246, targeting metastatic castration-resistant prostate cancer (mCRPC). Top-line results from an investigator-sponsored trial expected in Q1 2026.
• Roxadustat for MDS: Positive FDA Type C meeting regarding the regulatory path for roxadustat in treating anemia associated with lower-risk myelodysplastic syndromes (MDS). A pivotal Phase III trial protocol is set for submission in Q4 2025.

3. Forward Guidance and Outlook

• Revenue Guidance: Reiterated total revenues for 2025 to be between $6 million and $8 million.
• Operating Costs: Updated guidance for total operating costs and expenses for 2025 to be between $50 million and $60 million, reflecting a 70% reduction from 2024.
• Clinical Milestones: Anticipated interim results for FG-3246 Phase II trial in the second half of 2026 and top-line results from the IST in Q1 2026.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Despite improvements, the company still reported a significant net loss.
• Thrombotic Risk: Concerns regarding potential thrombotic risks in the roxadustat Phase III trial could limit patient enrollment, impacting the trial's feasibility and outcomes.
• Cash Guidance Impact: If FibroGen decides to self-fund the Phase III trial for roxadustat, it could shorten the cash runway into the second half of 2027, necessitating additional capital.

5. Notable Q&A Insights

• Thrombotic Risk: Management indicated uncertainty about the proportion of patients that might be excluded from the trial due to thrombotic risks, pending alignment with the FDA on inclusion/exclusion criteria.
• Cost of Phase III Trial: Estimated at $50 million to $60 million, which could affect cash guidance if pursued independently.
• Prostate Cancer Landscape: Discussion on CD46's expression levels relative to PSMA and potential correlations with treatment responses, with ongoing studies expected to provide more data.
• Decision Timeline for Roxadustat: Clarity on whether to proceed with the Phase III trial independently or seek partnerships is anticipated by Q2 2026, independent of FG-3246 developments.

Overall, FibroGen is positioned for potential growth with its ongoing clinical programs and improved financial health, but faces challenges related to trial risks and the need for strategic funding decisions.